Historical Valuation
Bicara Therapeutics Inc (BCAX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.50. The fair price of Bicara Therapeutics Inc (BCAX) is between -- to -- according to relative valuation methord.
Relative Value
Fair Zone
-----
Current Price：17.95
Fair
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
Bicara Therapeutics Inc (BCAX) has a current Price-to-Book (P/B) ratio of 2.22. Compared to its 3-year average P/B ratio of 1.37 , the current P/B ratio is approximately 61.53% higher. Relative to its 5-year average P/B ratio of 1.37, the current P/B ratio is about 61.53% higher. Bicara Therapeutics Inc (BCAX) has a Forward Free Cash Flow (FCF) yield of approximately -12.60%. Compared to its 3-year average FCF yield of -10.74%, the current FCF yield is approximately 17.33% lower. Relative to its 5-year average FCF yield of -10.74% , the current FCF yield is about 17.33% lower.
P/B
Median3y
1.37
Median5y
1.37
FCF Yield
Median3y
-10.74
Median5y
-10.74
Competitors Valuation Multiple
AI Analysis for BCAX
The average P/S ratio for BCAX competitors is 111.68, providing a benchmark for relative valuation. Bicara Therapeutics Inc Corp (BCAX.O) exhibits a P/S ratio of 0.00, which is -100% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
Performance Decomposition
AI Analysis for BCAX
1Y
3Y
5Y
Market capitalization of BCAX increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.
The secondary factor is the Unknown, contributed 0.00%to the performance.
Overall, the performance of BCAX in the past 1 year is driven by Unknown.
People Also Watch
Frequently Asked Questions
Is BCAX currently overvalued or undervalued?
Bicara Therapeutics Inc (BCAX) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -7.50. The fair price of Bicara Therapeutics Inc (BCAX) is between to according to relative valuation methord.
What is Bicara Therapeutics Inc (BCAX) fair value?
BCAX's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Bicara Therapeutics Inc (BCAX) is between to according to relative valuation methord.
How does BCAX's valuation metrics compare to the industry average?
The average P/S ratio for BCAX's competitors is 111.68, providing a benchmark for relative valuation. Bicara Therapeutics Inc Corp (BCAX) exhibits a P/S ratio of 0.00, which is -100.00% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.
What is the current P/B ratio for Bicara Therapeutics Inc (BCAX) as of Jan 10 2026?
As of Jan 10 2026, Bicara Therapeutics Inc (BCAX) has a P/B ratio of 2.22. This indicates that the market values BCAX at 2.22 times its book value.
What is the current FCF Yield for Bicara Therapeutics Inc (BCAX) as of Jan 10 2026?
As of Jan 10 2026, Bicara Therapeutics Inc (BCAX) has a FCF Yield of -12.60%. This means that for every dollar of Bicara Therapeutics Inc’s market capitalization, the company generates -12.60 cents in free cash flow.
What is the current Forward P/E ratio for Bicara Therapeutics Inc (BCAX) as of Jan 10 2026?
As of Jan 10 2026, Bicara Therapeutics Inc (BCAX) has a Forward P/E ratio of -5.71. This means the market is willing to pay $-5.71 for every dollar of Bicara Therapeutics Inc’s expected earnings over the next 12 months.
What is the current Forward P/S ratio for Bicara Therapeutics Inc (BCAX) as of Jan 10 2026?
As of Jan 10 2026, Bicara Therapeutics Inc (BCAX) has a Forward P/S ratio of 0.00. This means the market is valuing BCAX at $0.00 for every dollar of expected revenue over the next 12 months.